SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Eikon Therapeutics, Inc. (EIKN) Expects Cash Runway Into Q1 2028

Eikon reported $461.7M in cash, cash equivalents and marketable securities as of September 30, 2026, and expects it to fund operations into Q1 2028; no prior-period cash comparison was provided.Material DetailsContext by AI AnalystThis is a quarterly financial update during Eikon’s clinical develop…

EIKN

Related stories